AU2022212601A1 - Ip4-4,6 substituted derivative compounds - Google Patents
Ip4-4,6 substituted derivative compounds Download PDFInfo
- Publication number
- AU2022212601A1 AU2022212601A1 AU2022212601A AU2022212601A AU2022212601A1 AU 2022212601 A1 AU2022212601 A1 AU 2022212601A1 AU 2022212601 A AU2022212601 A AU 2022212601A AU 2022212601 A AU2022212601 A AU 2022212601A AU 2022212601 A1 AU2022212601 A1 AU 2022212601A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- salt
- aspects
- myo
- bis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/093—Polyol derivatives esterified at least twice by phosphoric acid groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
- C07F9/6518—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21382075.6 | 2021-01-29 | ||
| EP21382075.6A EP4036097A1 (en) | 2021-01-29 | 2021-01-29 | Ip4-4,6 substituted derivative compounds |
| PCT/EP2022/052164 WO2022162206A1 (en) | 2021-01-29 | 2022-01-31 | Ip4-4,6 substituted derivative compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2022212601A1 true AU2022212601A1 (en) | 2023-07-06 |
| AU2022212601A9 AU2022212601A9 (en) | 2025-04-10 |
Family
ID=74732816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022212601A Pending AU2022212601A1 (en) | 2021-01-29 | 2022-01-31 | Ip4-4,6 substituted derivative compounds |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240109924A1 (https=) |
| EP (2) | EP4036097A1 (https=) |
| JP (1) | JP2024504257A (https=) |
| KR (1) | KR20230132811A (https=) |
| CN (1) | CN116745304A (https=) |
| AR (1) | AR124717A1 (https=) |
| AU (1) | AU2022212601A1 (https=) |
| BR (1) | BR112023014549A2 (https=) |
| CA (1) | CA3202780A1 (https=) |
| IL (1) | IL303825A (https=) |
| MX (1) | MX2023008250A (https=) |
| TW (1) | TW202239414A (https=) |
| WO (1) | WO2022162206A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021380963A1 (en) * | 2020-11-20 | 2023-06-22 | ETH Zürich | Inositol hexakisphosphate analogues for treatment of calcification associated kidney diseases |
| AU2023313374A1 (en) * | 2022-07-29 | 2025-02-13 | Vifor (International) Ltd. | Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873355A (en) * | 1987-05-29 | 1989-10-10 | E. I. Du Pont De Nemours And Company | Process for regioselectively preparing phosphorylated inositols and other cyclitols |
| US4755612A (en) * | 1987-07-20 | 1988-07-05 | Merck & Co., Inc. | Intermediate compounds resulting from method for forming a dihydrogen-phosphate inositol |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| EP0431197A4 (en) * | 1989-06-28 | 1991-12-04 | Mitsui Toatsu Chemicals Inc. | Myoinositol derivative and method of production thereof, and phosphorylating agent and its use |
| ES2124303T3 (es) | 1992-03-25 | 1999-02-01 | Depomed Inc | Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa. |
| US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| US5834436A (en) * | 1993-04-09 | 1998-11-10 | The Regents Of The University Of California | Membrane-permeant second messengers |
| AU3290397A (en) | 1996-06-10 | 1998-01-07 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| WO1998055107A1 (en) | 1997-06-06 | 1998-12-10 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| HK1050135A1 (zh) | 1999-11-02 | 2003-06-13 | Depomed, Inc. | 用於促进将药物给予胃的饭後模式药理学诱导 |
| DE60123384T2 (de) | 2000-02-04 | 2007-08-02 | DepoMed, Inc., Menlo Park | Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert |
| US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| US6451808B1 (en) | 2000-10-17 | 2002-09-17 | Depomed, Inc. | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
| MXPA03011096A (es) | 2001-05-29 | 2004-12-06 | Depomed Dev Ltd | Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna. |
| US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| JP2005508358A (ja) | 2001-10-25 | 2005-03-31 | デポメド・インコーポレイテッド | 胃滞留型ロサルタン投与量を用いる治療方法 |
| US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| ES2232302B1 (es) * | 2003-11-07 | 2006-08-01 | Universitat De Les Illes Balears | Myo-inositol hexafosfato para uso topico. |
| ES2288126B2 (es) | 2006-06-01 | 2009-07-06 | Universitat De Les Illes Balears | Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis. |
| ES2332636B1 (es) | 2008-08-06 | 2011-02-10 | Universitat De Les Illes Balears | Composicion de liquido de dialisis. |
| EP2579036A1 (en) | 2011-10-06 | 2013-04-10 | Laboratorios Sanifit, S.L. | Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200 |
| JP6893037B2 (ja) | 2015-12-11 | 2021-06-23 | エーテーハー・チューリッヒＥＴＨ Ｚｕｒｉｃｈ | Ｃ．ｄｉｆｆｉｃｉｌｅ感染のための４，６−ジ−（Ｏ−チオホスフェート）−イノシトール−１，２，３，５−テトラ−Ｏ−スルフェート |
| DK3386548T3 (da) * | 2015-12-11 | 2021-05-25 | Eth Zuerich | Inositol-derivater til anvendelse i patologisk krystallisering |
| WO2019176693A1 (ja) * | 2018-03-15 | 2019-09-19 | 国立大学法人広島大学 | 骨外組織における骨形成関連因子又は石灰化関連因子の発現抑制剤 |
-
2021
- 2021-01-29 EP EP21382075.6A patent/EP4036097A1/en not_active Withdrawn
-
2022
- 2022-01-27 TW TW111103698A patent/TW202239414A/zh unknown
- 2022-01-28 AR ARP220100172A patent/AR124717A1/es unknown
- 2022-01-31 EP EP22703600.1A patent/EP4284809A1/en active Pending
- 2022-01-31 CA CA3202780A patent/CA3202780A1/en active Pending
- 2022-01-31 JP JP2023537515A patent/JP2024504257A/ja active Pending
- 2022-01-31 AU AU2022212601A patent/AU2022212601A1/en active Pending
- 2022-01-31 WO PCT/EP2022/052164 patent/WO2022162206A1/en not_active Ceased
- 2022-01-31 KR KR1020237027325A patent/KR20230132811A/ko active Pending
- 2022-01-31 BR BR112023014549A patent/BR112023014549A2/pt unknown
- 2022-01-31 US US18/274,805 patent/US20240109924A1/en active Pending
- 2022-01-31 MX MX2023008250A patent/MX2023008250A/es unknown
- 2022-01-31 CN CN202280012575.8A patent/CN116745304A/zh active Pending
- 2022-01-31 IL IL303825A patent/IL303825A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024504257A (ja) | 2024-01-31 |
| BR112023014549A2 (pt) | 2023-10-10 |
| CN116745304A (zh) | 2023-09-12 |
| WO2022162206A1 (en) | 2022-08-04 |
| AU2022212601A9 (en) | 2025-04-10 |
| AR124717A1 (es) | 2023-04-26 |
| EP4284809A1 (en) | 2023-12-06 |
| CA3202780A1 (en) | 2022-08-04 |
| EP4036097A1 (en) | 2022-08-03 |
| MX2023008250A (es) | 2023-07-26 |
| IL303825A (en) | 2023-08-01 |
| US20240109924A1 (en) | 2024-04-04 |
| KR20230132811A (ko) | 2023-09-18 |
| TW202239414A (zh) | 2022-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69600784T2 (de) | Proteinkinase-C-Inhibitor | |
| US12012467B2 (en) | Small molecule DCN1 inhibitors and therapeutic methods using the same | |
| ES3014225T3 (en) | Rapamycin derivatives | |
| US20240109924A1 (en) | Ip4-4,6 substituted derivative compounds | |
| NL8202626A (nl) | Derivaten van 9-(2-hydroxyethoxymethyl)guanine. | |
| EP4089102A1 (en) | Modulators of sortilin activity | |
| KR20190092440A (ko) | 야누스 키나제 억제제의 결정질 형태 | |
| WO2024023359A1 (en) | Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification | |
| CN115427418B (zh) | 一种肌醇衍生物及其用途 | |
| US20140142052A1 (en) | Phosphorylated polyols, pyrophosphates, and derivatives thereof having biological activity | |
| EA050725B1 (ru) | Замещенные производные соединений ip4-4,6 | |
| AU2023313051A1 (en) | Ip5 substituted compounds | |
| CN113999235A (zh) | 含氮杂环化合物的固体形式及其药物组合物和用途 | |
| US20160368944A1 (en) | Linked purine pterin hppk inhibitors useful as antibacterial agents | |
| HK40094155A (zh) | Ip4-4，6取代的衍生化合物 | |
| CN114423775B (zh) | 一类芳基葡糖苷衍生物及其制备方法和应用 | |
| EP2542560A2 (en) | Arylfluorophosphate inhibitors of intestinal apical membrane sodium/phosphate co-transport | |
| AU2017343643B2 (en) | HPPK inhibitors useful as antibacterial agents | |
| JP7829949B2 (ja) | リン酸エステル基を含有する化合物、それを含有する医薬組成物、その調製方法、及びその使用 | |
| HK40123408A (zh) | 用於治疗异位钙化、抑制进展和预防异位钙化的ip4-4，6取代的衍生物化合物 | |
| WO2023248010A2 (en) | Targeted modulators of jak3 for treatment of inflammatory and autoimmune diseases | |
| EP4353722A1 (en) | Phosphate of trifluoromethyl-substituted sulfonamide compound | |
| KR20250025414A (ko) | 시클로펜틸아데노신 유도체 및 이의 약학적 용도 | |
| CA2661131A1 (en) | New heterocyclic compounds containing nitrogen atoms or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same for treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished | ||
| PC1 | Assignment before grant (sect. 113) |
Owner name: VIFOR (INTERNATIONAL) LTD. Free format text: FORMER APPLICANT(S): SANIFIT THERAPEUTICS, S.A. |